ストックスクリーナーアプリを入手
36.85
5.02%
1.76
アフターアワーズ：
36.84
-0.010
-0.03%
Exelixis Inc (EXEL) 最新ニュース
Exelixis (EXEL) Stock Jumps Amid New Share Buyback Announcement - GuruFocus.com
Why Exelixis Stock Trounced the Market on Thursday - MSN
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday? - AOL
Why Exelixis Shares Are Skyrocketing: A Story of Triumph and Strategy - Jomfruland.net
Exelixis' (NASDAQ:EXEL) Earnings May Just Be The Starting Point - Yahoo Finance
Exelixis Inc.: Pipeline Expansion & Innovation to Build A Robust Portfolio! - Smartkarma
Exelixis Board Authorizes Additional Share Buyback Program of Up To $500 Million; Shares Advance After Hours - Marketscreener.com
Exelixis Approves Additional $500 Mln Stock Buyback Program - Nasdaq
Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program - The Bakersfield Californian
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes" - Nasdaq
Exelixis director Sue Gail Eckhardt sells shares worth $405,111 By Investing.com - Investing.com South Africa
Exelixis director George Poste sells $551,462 in stock By Investing.com - Investing.com Australia
Exelixis director Mary Beckerle sells $425,878 in stock By Investing.com - Investing.com Australia
Exelixis director Sue Gail Eckhardt sells shares worth $405,111 - Investing.com India
Exelixis director Freire Maria C sells $1.54 million in stock - Investing.com India
Exelixis director Mary Beckerle sells $425,878 in stock - Investing.com India
Exelixis director Freire Maria C sells $1.54 million in stock By Investing.com - Investing.com Nigeria
Exelixis Executives Sell Shares in February Transactions - TradingView
Exelixis looks to next-gen cancer drug as Cabometyx underwhelms again - PharmaLive
Exelixis's SWOT analysis: cabo patent win boosts stock outlook By Investing.com - Investing.com Nigeria
Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy? - MSN
Exelixis's SWOT analysis: cabo patent win boosts stock outlook - Investing.com
Exelixis falls after ASCO releases colorectal cancer data - MSN
International Markets and Exelixis (EXEL): A Deep Dive for Investors - Nasdaq
Five-year results see Exelixis’ RCC therapy extending overall survival - Yahoo Finance
Exelixis stock rating cut by Oppenheimer, price target to $33 from $41 - MSN
JMP Securities maintains Exelixis stock with $41 target - MSN
Exelixis Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Exelixis (NASDAQ:EXEL) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Exelixis (NASDAQ:EXEL) Stock Rating Lowered by StockNews.com - MarketBeat
State of Alaska Department of Revenue Decreases Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Q4 2024 Earnings Call Transcript - MSN
Piper Sandler Increases Exelixis (NASDAQ:EXEL) Price Target to $38.00 - MarketBeat
Sapient Capital LLC Invests $256,000 in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis (NASDAQ:EXEL) Receives "Buy" Rating from HC Wainwright - MarketBeat
Exelixis (EXEL) Q4 Earnings and Revenues Top Estimates - MSN
Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX - Business Wire
Exelixis (NASDAQ:EXEL) Given New $29.00 Price Target at Barclays - MarketBeat
Q3 Earnings Forecast for Exelixis Issued By Leerink Partnrs - MarketBeat
Citigroup Issues Positive Forecast for Exelixis (NASDAQ:EXEL) Stock Price - MarketBeat
Polaris Capital Management LLC Sells 16,900 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Empowered Funds LLC Takes $7.46 Million Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
EXELExelixis Inc Latest Stock News & Market Updates - StockTitan
Stifel Nicolaus Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) Stock - MarketBeat
Stifel raises Exelixis stock price target to $36, maintains hold - MSN
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy? - Nasdaq
Exelixis, Inc. (NASDAQ:EXEL) Holdings Lifted by Allspring Global Investments Holdings LLC - MarketBeat
Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit - BioSpace
FY2025 EPS Estimates for Exelixis Reduced by Leerink Partnrs - MarketBeat
Exelixis stock holds firm with $41 target from JMP Securities - MSN
Exelixis targets $5B Zanza sales by 2033 with multiple pivotal trials in progress - MSN
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):